- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alembic Pharma gets USFDA EIR for Karakhadi facility
![Alembic Pharma gets USFDA EIR for Karakhadi facility Alembic Pharma gets USFDA EIR for Karakhadi facility](https://medicaldialogues.in/h-upload/2020/04/16/750x450_127325-125386-usfda-inspection-1.webp)
Gujarat: Drugmaker, Alembic Pharma, has announced that the company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out at its New Injectable Facility (F-3) at Karakhadi, Gujarat.
The inspection was conducted from 28th January, 2021 to 5th February, 2021.
USFDA has also indicated that a compliance verification would be performed during re-inspection of the said facility in the next review cycle.
In February, Alembic Pharma had got five observations from US health regulator after inspection at its facility at Karkhadi, Gujarat.
Read also: Alembic Pharma Gujarat Facility Gets 5 USFDA Observations
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Read also: Alembic Pharma bags USFDA nod for Clomipramine Hydrochloride Capsules to treat OCD
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751